Disc Medicine, Inc. (IRON) Form 424B5 — Oct 21, 2026
Disc Medicine priced a $450 million follow-on offering of 6 million shares at $75.00, a roughly 5.6% discount to the prior close of $79.48, with a 900,000-share greenshoe and net proceeds of about $422.4 million. The raise comes just two days after positive APOLLO Phase 3 topline results for bitopertin in erythropoietic protoporphyria, which met all primary and secondary endpoints; the company plans to resubmit its NDA by end of 2026 with an FDA decision anticipated by mid-2027.
Key figures
- Gross Proceeds
- 450000000
- Offering Price
- 75
- Shares Offered
- 6000000
- Prior Close
- $79.48 (October 20, 2026)
- Net Proceeds
- $422.4 million
- Atm Remaining
- $189.9 million
- Greenshoe Shares
- 900000
- Cash Runway Post Offering
- into 2030 (into 2029 without proceeds)
- Immediate Dilution Per Share
- $50.95
- Cash Sept30 2026 preliminary
- $682.8 million
- Underwriting Discount Per Share
- 4.5
- Shares Outstanding Post Offering
- 44,345,666 (45,245,666 with full greenshoe)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.